H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $12 from $30 and keeps a Buy rating on the shares. The firm cites the impact of the most recent equity financing in February of this year, future potential equity issuances and the exercise of warrants for the target cut.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue